drugset / Trial / NCT00369317
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
NaSingle-groupOpen-labelTreatment
Summary
This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Timeline
- Start
- 2007-03
- Primary completion
- 2013-12-01
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Daunorubicin | Small molecule | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Thioguanine | Small molecule | — | Oral |
| Subject | asparaginase | Protein / enzyme biologic | — | Intramuscular |
Indications
acute basophilic leukemia
acute erythroid leukemia
acute monocytic leukemia
acute myeloblastic leukemia with maturation
acute myeloblastic leukemia without maturation
acute myeloid leukemia with minimal differentiation
acute myelomonocytic leukemia M4
childhood acute megakaryoblastic leukemia
childhood acute myeloid leukemia
childhood myelodysplastic syndrome